



Verona Pharma

21 January 2016

Director Dealing

RNS Number : 6095M
Verona Pharma PLC
21 January 2016

Verona Pharma plc
("Verona Pharma" or the "Company")

Director Dealing

21 January 2016, Cardiff - Verona Pharma plc (AIM: VRP) received notification that on 20 January 2016 David Ebsworth, Director of the Company, purchased 400,000 ordinary shares of 0.1 pence each of the Company ("Ordinary Shares") at a price of 2.5 pence per Ordinary Share.

Following the transaction David Ebsworth has a total interest of 4,599,774 Ordinary Shares, representing 0.46% of the total voting rights.

-Ends-

For further information please contact:

Verona Pharma plc **Tel: +44 (0) 20 3283 4200**
Jan-Anders Karlsson, Chief Executive
Officer

N+1 Singer **Tel: +44 (0)20 7496 3000**
Aubrey Powell / Jen Boorer

FTI Consulting **Tel: +44 (0)20 3727 1000**
Simon Conway / Stephanie Cuthbert /
Natalie Garland-Collins

Notes to Editors

About Verona Pharma plc

Verona Pharma plc is a UK-based clinical stage biopharmaceutical company

focused on the development of innovative prescription medicines to treat respiratory diseases with significant unmet medical needs, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis.

Verona Pharma's lead drug, RPL554, is a first-in-class drug currently in Phase II trials as a nebulised treatment for acute exacerbations of COPD in the hospital setting. The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both bronchodilator and anti-inflammatory effects, which are essential to the improvement of patients with COPD and asthma.

Verona Pharma is also building a broader portfolio of RPL554-containing products to maximise its benefit to patients and its value. This includes the very significant markets for COPD and asthma maintenance therapy. The Company is also exploring the potential of the drug in different diseases, such as cystic fibrosis, where it is in pre-clinical testing and has received a Venture and Innovation Award from the Cystic Fibrosis Trust.

This information is provided by RNS
The company news service from the London Stock Exchange

END

RDSSSEDFEFFMSEEF

For further information please contact: Verona Pharma plc

Verona Pharma plc

Jan-Anders Karlsson, CEO
Tel: +44 (0)20 3283 4200
info@veronapharma.com

Stifel Nicolaus Europe Ltd (Nominated Adviser and UK Broker)

Jonathan Senior / Stewart Wallace
Tel: +44 (0)20 7710 7600

FTI Consulting

Simon Conway / Natalie Garland-Collins
Tel: +44 (0)20 3727 1000
veronapharma@fticonsulting.com

ICR, Inc. (US Media and Investor enquiries)

James Heins

Tel: +1 203-682-8251

James.Heins@icrinc.com

Stephanie Carrington

Tel. +1 646-277-1282

Stephanie.Carrington@icrinc.com

About Verona Pharma plc

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo and has shown clinically meaningful and statistically significant improvements in lung function when added to two commonly used bronchodilators as compared to either bronchodilator administered as a single agent. RPL554 has also shown anti-inflammatory effects and been well tolerated in clinical trials. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma.

Forward Looking Statements

This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the development of DPI and MDI formulations of RPL554 and the potential for these formulations to increase the market opportunity for the product, if approved.

These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
